Vascular device developer Conor Medsystems has received European CE Mark approval for the use of its UniStar cobalt chromium bare-metal coronary stent for the treatment of de novo coronary artery lesions.
The vendor reported that it has filed a CE Mark application for its CoStar cobalt chromium paclitaxel-eluting stent. Conor said it anticipates receiving CE Mark approval of the CoStar stent in the second half of 2005. Pending regulatory approval, the CoStar stent will be marketed in Europe, Latin America, and parts of Asia by the company's distribution partner, Biotronik of Bulach, Switzerland.
In March, a limited-market release of the CoStar stent began in India through Conor's South Asian distribution partner, Interventional Technologies, according to the Menlo Park, CA-based firm.
By AuntMinnie.com staff writers
May 10, 2005
Related Reading
Conor Medsystems inks distribution deal, May 27, 2004
Conor Medsystems releases PISCES data, May 26, 2004
Conor Medsystems completes paclitaxel stent trial enrollment, March 25, 2004
Copyright © 2005 AuntMinnie.com
